Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, signed a global license agreement...
You must be a Standard 1 Year member to access this content.
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, announced its strategic collaboration...
You must be a Standard 1 Year member to access this content.
Cooley advised Cholesgen on the deal. Cholesgen (Shanghai) Co.Ltd. announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with...
You must be a Standard 1 Year member to access this content.
Cooley advised NeuExcell Therapeutics on the deal. NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, announced its $15 million+ Series Pre-A+ financing round. Investors in the round...
You must be a Standard 1 Year member to access this content.
